Clinical trials: Breast Cancer, Female
Cancer, Cancer Diagnosis
Avera Cancer Sequencing and Analytics Protocol (ASAP)
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system.
- Conditions
- Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer
- Trial name
- ASAP (NCT05142033)
- Where
- 6 sites in United States
- Volunteers
- 25,000 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Breast Cancer Female
Sienna+MR Long-term Uptake
In a previous study in 2012/2013 patients were injected a superparamagnetic iron oxide for sentinel lymph node detection. In this follow up study we want to investigate how much of this tracer is still detectable.
- Trial name
- NCT03243435
- Testing
- Native 1,5 Tesla breast MRI
- Where
- Switzerland
- Volunteers
- 34 people
- Sponsor
- Kantonsspital Baden
Breast Carcinoma
A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer
This clinical trial studies whether a patient navigation (PN) intervention can be used to improve risk management among women at high risk of breast cancer.
- Trial name
- NCT06950008
- Testing
- Educational Intervention, Patient Navigation, Survey Administration
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Hormone Receptor Positive (HR+) Breast Cancer
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of patients in the Cohort MAP.
- Trial name
- NCT05108740
- Testing
- everolimus
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Ovarian Cancer
Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers
The aim of this trial is an evaluation of the effectiveness of intermittent fasting as a supplementary therapy in patients with breast cancer and ovarian cancer in respect to quality of life, reduction of side effects and…
- Trial name
- FIT2 (NCT03162289)
- Testing
- Fasting, Vegan
- Where
- 8 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Breast Cancer
Effectiveness of Liquid Crystal Contact Thermography in Detecting Pathological Changes in Female Breasts
The study is designed to evaluate the effectiveness of liquid crystal contact thermography in detecting pathological changes in female breasts compared to standard diagnostic methods.
- Trial name
- NCT03735550
- Testing
- Contact thermographic breast examination device
- Where
- 24 sites in Poland
- Volunteers
- 3,000 people
- Sponsor
- Jagiellonian University
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Colorectal Cancer (CRC), Endometrial Cancer
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2).
- Conditions
- Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer
- Trial name
- NCT02646748
- Testing
- Pembrolizumab, itacitinib, INCB050465
- Where
- 17 sites in United States
- Volunteers
- 159 people
- Sponsor
- Incyte Corporation
Breast Cancer and Ovarian Cancer
Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.
- Trial name
- NCT03055143
- Testing
- SPARC-08-038, Ref-08-038
- Volunteers
- 29 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Breast Neoplasm Female, Financial Toxicity
Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China
The goal of this pilot study is to access the feasibility and impact of a financial navigation program on improving financial toxicity among patients with breast cancer in China.
- Conditions
- Breast Neoplasm Female, Financial Toxicity, Financial Navigation
- Trial name
- NCT06355440
- Testing
- Financial Navigation, Usual Care
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Fudan University
Healthy Volunteers, Pharmacokinetics
Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate
Evaluation of the potential perpetrator effect of BAY1841788 (ODM-201) on rosuvastatin pharmacokinetics. PK of BAY1841788 (ODM-201) after single and repeated administration in male and female subjects.
- Conditions
- Healthy Volunteers, Pharmacokinetics, Drug Interaction
- Trial name
- NCT02671097
- Testing
- Rosuvastatin, BAY1841788 (ODM-201)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
Breast Cancer, Esophageal Cancer
Brodalumab in the Treatment of Immune-Related Adverse Events
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy.
- Conditions
- Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT06673329
- Testing
- Brodalumab, CT scan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brian Henick, MD
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer…
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative
- Trial name
- NCT02208375
- Testing
- Capivasertib, Laboratory Biomarker Analysis, Olaparib
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- M.D. Anderson Cancer Center
Gynecologic Cancer, Urologic Cancer
Web-Based Application for Monitoring Radiation Therapy Complications in Cancer Patients
Cancer treatment is multidisciplinary and may include radiotherapy. Treatment-related complications represent a burden for patients and the healthcare system.
- Conditions
- Gynecologic Cancer, Urologic Cancer, Breast Cancer
- Trial name
- NCT07416630
- Testing
- Web-Based Application for PROM Monitoring During Radiotherapy
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Cancer Recurrence
Fear of Recurrence Pilot Intervention for Women With Breast Cancer
The primary objective of this pilot study is to examine the feasibility and acceptability of a randomized, controlled study of a mindfulness and values-based living intervention targeted at reducing fear of recurrence in breast…
- Trial name
- WiLLoW (NCT01354041)
- Testing
- Acceptance and Commitment Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896857
- Testing
- RNA analysis, polymerase chain reaction, protein expression analysis
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Solid Tumor, Adult
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT05230186
- Testing
- Tumor Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- TScan Therapeutics, Inc.
Breast Neoplasm
Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer
Adapted physical activity (APA) was recognized as a non-drug therapy by the French Health Authority (HAS) in 2011. Very few studies have examined the efficiency of APA programs during the active phase of treatment in cancer…
- Trial name
- EMEAPA (NCT05949983)
- Testing
- APA Program, Recommendations for physical activity
- Where
- France
- Volunteers
- 866 people
- Sponsor
- University Hospital, Toulouse